Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
CC transcript
Appointed director
Asset disposition
Acq. announced

NEKTAR THERAPEUTICS (NKTR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Nektar Therapeutics Reports Second Quarter 2023 Financial Results"
08/07/2023 8-K Investor presentation
Docs: "Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company"
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 8-K Quarterly results
Docs: "Nektar Therapeutics Reports First Quarter 2023 Financial Results"
04/27/2023 8-K Quarterly results
04/17/2023 8-K Quarterly results
03/13/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Nektar Therapeutics Vivian Wu"
02/28/2023 8-K Quarterly results
Docs: "Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results"
02/23/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "PRESENTATION TITLED "PHASE 2 ISLAND STUDY OF REZPEG IN SLE"",
"Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus"
01/09/2023 8-K Quarterly results
12/22/2022 8-K Quarterly results
12/16/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
10/11/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "ANNOUNCEMENT BY NEKTAR THERAPEUTICS",
"ANNOUNCEMENT BY PURETECH HEALTH PLC"
10/07/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
07/01/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
05/02/2022 8-K Quarterly results
04/25/2022 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook"
04/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin in Combination with Opdivo"
03/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin in Combination with Opdivo in Previously Untreated Unresectable or Metastatic Melanoma"
02/28/2022 8-K Quarterly results
01/11/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure  Interactive Data
11/15/2021 8-K Appointed a new director
11/04/2021 8-K Quarterly results
Docs: "Nektar Therapeutics Reports Third Quarter 2021 Financial Results"
08/05/2021 8-K Quarterly results
Docs: "Nektar Therapeutics Reports Second Quarter 2021 Financial Results"
06/15/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/17/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy